Immunic, Inc. announced positive interim data from its phase 2 callIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes that this data shows biomarker evidence that vidofludimuscium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confir med disability progression based on the expanded disability status scale (EDSS).

Anticipated MS Clinical Milestones: Top-line data from the phase 2 callIPER trialof vidofludimus sodium in PMS is expected in April of 2025; Data from the interim analysis of the phase 3 ENSURE program of vidofludimus carbon carbon carbonate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.